Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Marco L. Davila"'
Autor:
Marco L. Davila, Kendra Sweet, Linda Kelley, Bin Yu, Xuefeng Wang, Justin C. Boucher, Ho-chien Tsai, Nolan J. Beatty, Jeffrey E. Lancet, Yongliang Zhang, Asmita Mishra, Gongbo Li, Bishwas Shrestha
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
Supplemental Digital Content is available in the text.
Adoptive cell therapy with ex vivo expanded tumor infiltrating lymphocytes or gene engineering T cells expressing chimeric antigen receptors (CAR) is a promising treatment for cancer patient
Adoptive cell therapy with ex vivo expanded tumor infiltrating lymphocytes or gene engineering T cells expressing chimeric antigen receptors (CAR) is a promising treatment for cancer patient
Publikováno v:
Expert opinion on biological therapy. 21(5)
Chimeric antigen receptor T (CAR T) cell therapy has revolutionized the treatment of relapsed and refractory hematologic malignancies leading to their integration into treatment algorithms. Tisagen...
Publikováno v:
J Clin Invest
Chimeric antigen receptor (CAR) T cell therapy has shown considerable promise for hematologic malignancies, leading to the US Food and Drug Administration approval of two CAR T cell-based therapies for the treatment of B cell acute lymphoblastic leuk
Publikováno v:
Handbook of Hematologic Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62508319198dcd75e57e7f931dd987fd
https://doi.org/10.1891/9780826149770.0055
https://doi.org/10.1891/9780826149770.0055
Autor:
Marco L. Davila, Christina A Bachmeier
Publikováno v:
Best Practice & Research Clinical Haematology. 34:101307
Autor:
Marco L. Davila
Publikováno v:
Blood. 132(8)
In this issue of Blood , Rossi et al report that the heterogeneity of personalized chimeric antigen receptor (CAR) T cells has limited the ability to identify product attributes that enhance patient outcomes, but they have showed that by using single
Autor:
Michael D. Jain, Marco L. Davila, Young-Chul Kim, Michael A. Vogelbaum, Sepideh Mokhtari, Lazaryan Aleksandr, Justin Asquith, Peter A. Forsyth, Solmaz Sahebjam, Rawan Faramand, Frederick L. Locke, Christina A Bachmeier, Edwin Peguero
Publikováno v:
Neuro Oncol
INTRODUCTION Severe Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurs in ~ 30% of Diffuse Large B Cell Lymphoma (DLBCL) patients treated with CAR-T cell therapy. The current treatment for severe ICANS is glucocorticoids, and this
Autor:
Austin J. Sim, Aleksandr Lazaryan, Farhad Khimani, Bijal D. Shah, Nicholas Figura, Timothy J. Robinson, Marco L. Davila, Michael D. Jain, Sungjune Kim, Frederick L. Locke, Julio C. Chavez
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 108:E51
Autor:
Marco L. Davila, Renier J. Brentjens
Publikováno v:
Best Pract Res Clin Haematol
Autor:
Marco L. Davila, Justin C. Boucher
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:S43-S44